Yervoy - references pg 2

Article

References: 1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011. 2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8);711-723. 3. Wolchock JD, Weber JS, Hamid O, et al, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrspective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9-14. 4. Data on file. YERV 008. Bristol-Myers Squibb. Princeton, NJ April 2011.

References:
1. YERVOY package insert. Princeton, NJ: Bristol-Myers Squibb; 2011.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8);711-723.
3. Wolchock JD, Weber JS, Hamid O, et al, Ipilimumab efficacy and safety in patients with advanced melanoma: a retrspective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9-14.
4. Data on file. YERV 008. Bristol-Myers Squibb. Princeton, NJ April 2011.

Recent Videos
Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
2 experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Related Content